HomeCompareTRVN vs MRK

TRVN vs MRK: Dividend Comparison 2026

TRVN yields 18018.02% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRVN wins by $18633001307266260992.00M in total portfolio value
10 years
TRVN
TRVN
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full TRVN calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TRVN vs MRK

📍 TRVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRVNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRVN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRVN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRVN
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, TRVN beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRVN + MRK for your $10,000?

TRVN: 50%MRK: 50%
100% MRK50/50100% TRVN
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TRVN
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRVN buys
0
MRK buys
0
No recent congressional trades found for TRVN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRVNMRK
Forward yield18018.02%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$18633001307266260992.00M$56.8K
Annual income after 10y$18,431,768,966,926,280,000,000,000.00$9,798.13
Total dividends collected$18619711198521020416.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: TRVN vs MRK ($10,000, DRIP)

YearTRVN PortfolioTRVN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,812,502$1,801,801.80$11,206$366.19+$1.80MTRVN
2$307,151,434$305,212,057.22$12,650$502.35+$307.14MTRVN
3$48,667,022,851$48,338,370,816.14$14,407$694.19+$48667.01MTRVN
4$7,210,053,431,136$7,157,979,716,686.14$16,585$967.82+$7210053.41MTRVN
5$998,798,584,418,300$991,083,827,246,983.60$19,342$1,363.89+$998798584.40MTRVN
6$129,380,351,742,642,780$128,311,637,257,315,230.00$22,913$1,947.19+$129380351742.62MTRVN
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$27,662$2,823.89+$15672057030122.29MTRVN
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$34,159$4,173.35+$1775286122699574.75MTRVN
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$43,337$6,308.80+$188067607794372832.00MTRVN
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$56,776$9,798.13+$18633001307266260992.00MTRVN

TRVN vs MRK: Complete Analysis 2026

TRVNStock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Full TRVN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TRVN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRVN vs SCHDTRVN vs JEPITRVN vs OTRVN vs KOTRVN vs MAINTRVN vs JNJTRVN vs ABBVTRVN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.